Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer

被引：0
|
作者：
Morizane, Chigusa [1 ]
Ikeda, Masafumi [2 ]
Ueno, Makoto [3 ]
Kobayashi, Satoshi [3 ]
Ohno, Izumi [2 ]
Kondo, Shunsuke [1 ]
Okano, Naohiro [4 ]
Kimura, Keisuke [5 ]
Asada, Suguru [5 ]
Namba, Yoshinobu [5 ]
Okusaka, Takuji [1 ]
Furuse, Junji [4 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[4] Kyorin Univ, Fac Med, Mitaka, Tokyo, Japan
[5] Ono Pharmaceut Co Ltd, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz339.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2 - 2 - 4
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
    Ikeda, Masafumi
    Ueno, Makoto
    Morizane, Chigusa
    Kobayashi, Satoshi
    Ohno, Izumi
    Kondo, Shunsuke
    Okano, Naohiro
    Kimura, Keisuke
    Asada, Suguru
    Namba, Yoshinobu
    Okusaka, Takuji
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
    Ueno, Makoto
    Ikeda, Masafumi
    Morizane, Chigusa
    Kobayashi, Satoshi
    Ohno, Izumi
    Kondo, Shunsuke
    Okano, Naohiro
    Kimura, Keisuke
    Asada, Suguru
    Namba, Yoshinobu
    Okusaka, Takuji
    Furuse, Junji
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08): : 611 - 621
  • [3] Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
    Feng, Kaichao
    Liu, Yang
    Zhao, Yongtian
    Yang, Qingming
    Dong, Liang
    Liu, Jiejie
    Li, Xiang
    Zhao, Zhikun
    Mei, Qian
    Han, Weidong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [4] A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer.
    Sahai, Vaibhav
    Griffith, Kent A.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.
    Sahai, Vaibhav
    Griffith, Kent A.
    Beg, Muhammad Shaalan
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01
    Sahai, Vaibhav
    Griffith, Kent A.
    Beg, Muhammad S.
    Shaib, Walid L.
    Mahalingam, Devalingam
    Zhen, David B.
    Deming, Dustin A.
    Zalupski, Mark M.
    CANCER, 2022, 128 (19) : 3523 - 3530
  • [7] A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).
    Sahai, Vaibhav
    Griffith, Kent A.
    Beg, Muhammad Shaalan
    Shaib, Walid Labib
    Mahalingam, Devalingam
    Zhen, David Bing
    Deming, Dustin A.
    Dey, Sumi
    Mendiratta-Lala, Mishal
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] EVALUATION OF CHEMOTHERAPY WITH CISPLATIN-GEMCITABINE AFTER FAILURE OF GEMCITABINE MONOTHERAPY FOR UNRESECTABLE OR RECURRENT BILIARY TRACT CANCER
    Kameda, R.
    Ando, T.
    Kobayashi, S.
    Ueno, M.
    Ohkawa, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 162 - 162
  • [9] Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
    Franses, Joseph W.
    Hong, Theodore S.
    Zhu, Andrew X.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (08): : 575 - 577
  • [10] SAFETY OF COMBINATION CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE FOR UNRESECTABLE BILIARY TRACT CANCER
    Shibata, Y.
    Kotani, H.
    Ogawa, K.
    Takahashi, M.
    Takase, M.
    Shibata, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 162 - 162
12345